Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. The Company later changed its name to Galapagos NV (link to new Galapagos NV Wikipedia listing) and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.

Onno van de Stolpe is the CEO of the company.

Contents 1 See also 2 References 3 Source 4 External links

[edit] See also

• FlandersBio

[edit] References

• Edwards PJ., The impact of parallel chemistry in drug discovery, IDrugs. 2006 May;9(5):347-53.

[edit] Source

• Galapagos Genomics gaat zelf medicijnen ontwikkelen (Dutch)
• Een rotsvast geloof in de Vlaamse biotech

[edit] External links

• Galapagos Genomics

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. v • d • e